SynthesisJournal of racial and ethnic health disparities2015
Racial and Ethnic Disparities in Adverse Drug Events: A Systematic Review of the Literature.
Synthesis in Journal of racial and ethnic health disparities, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The safety of health care for ethnic minority patients: a systematic review.International journal for equity in health · 2020Pooled it
- Development and validation of a risk-score model for opioid overdose using a national claims database.Scientific reports · 2022Trial
- Pharmacokinetics, Safety, and Tolerability of Single- and Multiple-Dose Once-Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo-Controlled Study.Clinical pharmacology in drug development · 2020Trial
- Machine learning evaluation of racial and ethnic inclusion under alternative cost-based approaches to Medicare Medication Therapy Management eligibility.Journal of managed care & specialty pharmacy · 2026Article
- Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study.Neurology and therapy · 2026Article
- Assessment of drug-related problems and associated factors among patients with chronic obstructive pulmonary disease in Dailekh, Nepal: a cross-sectional study.Scientific reports · 2026Article
- When health research feels relevant: a data report on perceived research applicability and health behavior intentions.Frontiers in psychology · 2026Article
- The ethnicity and gut microbiota hypothesis: analyzing multifactorial interactions and their health implications.Frontiers in microbiology · 2026Review
- Impact of a Novel Virtual Rounding Queue Software on Nurse and Family Presence for Rounds in the Neonatal Intensive Care Unit: A Pilot Study.Academic pediatrics · 2025Article
- Precision medicine on a budget in Africa: using existing genetic data to mitigate adverse drug reactions to conventional cancer drugs.Frontiers in bioinformatics · 2025Article
- Inequities in Inpatient Pediatric Patient Safety Events by Category.Hospital pediatrics · 2024Article
- Adverse events associated with AstraZeneca COVID-19 vaccine among adults in Greater Kampala, Uganda: a cross-sectional study.African health sciences · 2024Article
- Novel genomic variants influencing methotrexate delayed clearance in pediatric patients with acute lymphoblastic leukemia.Frontiers in pharmacology · 2024Article
- Article
- Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects.Dermatology and therapy · 2023Article
- Ethnicity, Race and Skin Color: Challenges and Opportunities for Atopic Dermatitis Clinical Trials.Journal of clinical medicine · 2023Review
- Adverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy.CNS drugs · 2023Article
- Medication Regimen Complexity Index Score at Admission as a Predictor of Inpatient Outcomes: A Machine Learning Approach.International journal of environmental research and public health · 2023Article
- Racial disparities in breast cancer treatment patterns and treatment related adverse events.Scientific reports · 2023Article
- How and why might interprofessional patient- and family-centered rounds improve outcomes among healthcare teams and hospitalized patients? A conceptual framework informed by scoping and narrative literature review methods.Frontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2014 National Action Plan for Adverse Drug Event Prevention has recognized adverse drug events (ADEs) as a national priority in order to facilitate a nationwide reduction in patient harms from these events. Throughout this effort, it will be integral to identify populations that may be at particular risk in order to improve care for these patients. We have undertaken a systematic review to evaluate the evidence regarding racial or ethnic disparities in ADEs with particular emphasis on anticoagulants, diabetes agents, and opioids due to the clinical significance and preventability of ADEs associated with these medication classes. From an initial search yielding 3302 studies, we identified 40 eligible studies. Twenty-seven of these included studies demonstrated the presence of a racial or ethnic disparity. There was no consistent evidence for racial or ethnic disparities in the eight studies of ADEs in general. Asians were most frequently determined to be at higher risk of anticoagulant-related ADEs, and black patients were most frequently determined to be at higher risk for diabetes agents-related ADEs. Whites were most frequently identified as at increased risk for opioid-related ADEs. However, few of these studies were specifically designed to evaluate racial or ethnic disparities, lacking a standardized approach to racial/ethnic categorization as well as control for potential confounders. We suggest the need for targeted interventions to reduce ADEs in populations that may be at increased risk, and we suggest strategies for future research.
Indexed as
Identifiers
26863559What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.